Iovance Biotherapeutics, Inc.

As of June 30, 2026, Iovance Biotherapeutics Inc carries a market capitalization of 1.34B, placing it among publicly traded companies globally. Its enterprise value stands at 1.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Iovance Biotherapeutics Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Iovance Biotherapeutics Inc has 452.97M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.61, and the price-to-book ratio stands at 2.25.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.28B versus a market cap of 1.34B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Iovance Biotherapeutics Inc maintains a current ratio of 4.35, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Iovance Biotherapeutics Inc posted a negative return on equity (ROE) of -40.36, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.76, reflecting losses generated across the asset base. The company generates approximately 279,053.64 in revenue per employee across its workforce of 940.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.18 indicates how many times Iovance Biotherapeutics Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Iovance Biotherapeutics Inc recorded an income tax benefit of -3.44M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -237.32M and -233.88M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Iovance Biotherapeutics Inc generated 262.52M in revenue and converted that into -233.88M in net income, yielding earnings per share of -0.57. EBITDA reached -207.07M, while operating income came in at -239.25M.

As of June 30, 2026, Iovance Biotherapeutics Inc holds 89.48M in cash and equivalents against 35.00M in total debt, resulting in a net debt position of -89.48M. Total book value stands at 594.60M, with working capital of 288.73M providing operational flexibility.

Iovance Biotherapeutics Inc produced -213.41M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -26.02M in capital expenditures, free cash flow totaled -239.44M - equivalent to -0.58 per share.

Over the twelve months ended June 30, 2026, Iovance Biotherapeutics Inc posted a gross margin of 48.40, reflecting its pricing power and cost economics. The operating margin of -91.14 and net profit margin of -89.09 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.40, meaning Iovance Biotherapeutics Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Iovance Biotherapeutics Inc's most recent stock split took place on September 26, 2013 with a 100:1 split ratio.

As of June 30, 2026, Iovance Biotherapeutics Inc has an Altman Z-Score of -1.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.